Dendritic Cell-Based Vaccines in Cancer

摘要: Therapeutic vaccines that can activate the immune system to destroy malignancies hold promise of a low-toxicity, precisely targeted anticancer treatment modality. Because dendritic cells (DCs) are central activation antigen-specific responses, DCs loaded with tumor antigens considerable interest as therapeutic vaccines. Preclinical studies have demonstrated potency DC-based immunizations in promoting rejection. Continued preclinical and clinical assessing number important parameters regarding formulation administration regimen provided support for phase I II studies. Thus far, DC-mediated been well tolerated, few toxicities reported. Tumor regression has reported up 30% patients, particularly immunologically sensitive tumors such melanoma. Biologic activity, measured T cells, is 100% patients immunized against potent recall antigens, tetanus toxoid, those antigens. Current trials increasingly testing minimal residual disease, following attempted curative surgery or high-dose chemotherapy stem-cell where benefit likely be greatest. Newer strategies focusing on further modifications increase their immuno stimulatory potency. These include newer methods antigen loading, better techniques DC maturation, enhance polarization ensure induction helper cell type 1 adjunctive cytokines augment response immunization.